Aktis Oncology Welcomes Mike Sherman to Its Board, Amplifying Leadership in Oncology Drug Development

Aktis Oncology Strengthens Leadership with Mike Sherman

BOSTON, Aug. 7, 2025 – Aktis Oncology, Inc., a pioneering clinical-stage oncology firm, has officially appointed Mike Sherman to its Board of Directors. With over 30 years of leadership experience in oncology drug development, Sherman is set to play a vital role in steering the company towards its mission of unlocking the potential of targeted radiopharmaceuticals.

Joe Roden, the President and CEO of Aktis, expressed his enthusiasm about Sherman’s appointment, emphasizing the valuable expertise he brings from leading successful oncology firms through critical development milestones. Sherman’s comprehensive understanding of the oncology landscape is seen as crucial as Aktis proceeds with its innovative pipeline, particularly the NECTINIUM-2 Phase Ib clinical trial, which evaluates the drug AKY-1189 for treating various aggressive cancers.

A Rich Background in Life Sciences

Mike Sherman’s career is marked by significant contributions to the life sciences sector. His previous roles include positions as CEO and Board Director for both public and private entities focused on oncology therapeutics. Currently, he serves as an independent director for Werewolf Therapeutics and Tolremo Therapeutics, where his insight into novel cancer therapies is shaping future medication development.

Before these roles, Sherman was Chairman of Chimerix, where he led the company through its remarkable $935 million acquisition by Jazz Pharmaceuticals in 2025. His earlier tenure as CEO at Chimerix was similarly impactful, where he honed his skills in corporate leadership and strategic transactions. During his time with Endocyte Inc., Sherman successfully navigated the company’s transition from a modest market cap of $200 million to an impressive $2.1 billion buyout by Novartis, facilitated by the FDA-approved radiopharmaceutical PLUVICTO®, known for its effectiveness in advanced prostate cancer treatments.

Sherman’s academic credentials include a BA in Economics from DePauw University and an MBA from the prestigious Tuck School of Business at Dartmouth, which underpin his business acumen and strategic insight in the dynamic landscape of oncology.

Excitement for the Future

Reflecting on his new role, Sherman stated, “I am excited to join the Aktis Board of Directors at such a pivotal time for the company.” He believes that Aktis is establishing itself as a leader in the burgeoning field of radiopharmaceuticals. Sherman’s enthusiasm stems from recognizing the transformative potential of Aktis’s proprietary miniprotein radioconjugate technology, designed to create treatment options for patients with hard-to-treat cancers.

He acknowledged the company’s progress with its clinical pipeline and the strategic collaboration with Eli Lilly, which looks to harness the miniprotein platform to develop groundbreaking radioconjugates beyond Aktis’s existing frameworks. As a key player on the Board, Sherman is poised to facilitate the advancement of these promising therapies, aiming to ensure that they reach patients in need.

About Aktis Oncology

Aktis Oncology, Inc. is dedicated to revolutionizing cancer treatment through targeted radiopharmaceuticals, aiming to address the gaps left by existing technologies. Their lead program focuses on Nectin-4, a tumor-associated antigen present in various solid tumors. Born from MPM BioImpact, Aktis has crafted a unique miniprotein radioconjugate platform aimed at improving tumor-targeting agents, optimizing cancer treatment efficacy while minimizing side effects.

The platform is also designed to facilitate hybrid isotopes, allowing for imaging to confirm target engagement ahead of treatment, hence augmenting the precision in applying radioisotopes therapeutically. With their ongoing collaboration with Eli Lilly, Aktis anticipates expanding the reach and effectiveness of its innovative treatment strategies.

For further details about Aktis Oncology, visit www.aktisoncology.com.

Media Contact:
Sean Leous
ICR Healthcare
(646) 866-4012
[email protected]

Investor Contact:
Peter Vozzo
ICR Healthcare
(443) 213-0505
[email protected]